PacBio Announces New Agreement with Novogene to Purchase Ten Sequel Systems
August 02 2017 - 4:02PM
Pacific Biosciences of California, Inc. (Nasdaq:PACB) and Novogene
Corporation today announced a new agreement by Novogene to purchase
10 Sequel® Systems, giving the DNA sequencing service provider the
capacity to run up to 20 Sequel Systems at a time.
Novogene, a leading provider of genomic services and solutions
with cutting edge next-generation sequencing and bioinformatics
expertise, is the largest user of PacBio’s Sequel Systems in the
world. The service provider has ramped its use of the system
dramatically since earlier in the year when it acquired acesss to
the first 10 Sequel Systems through the Nanjing Yangzi State-Owned
Investment Group in China.
The Sequel System, based on PacBio’s unique Single Molecule,
Real-Time (SMRT®) technology, provides an unmatched depth of
genetic information through exceptionally long sequencing reads,
uniform coverage, and the highest consensus accuracy available
today. The technology allows scientists to go beyond fragmented
draft genomes and generate the most comprehensive de
novo assemblies.
“The overwhelming demand for SMRT Sequencing in
the few months since we began running the Sequel Systems has
required us to double our capacity in a short amount of time,” said
Ruiqiang Li, Ph.D., Founder and CEO of Novogene. “Some of the large
projects we have planned include building a database of structural
variants in 1,000 Chinese individuals as part of the Chinese
precision medicine initiative. In addition, we have partnered
with the Global Ant Genomics Alliance to sequence 300 different
species of ants to provide a comprehensive look at genomic
diversity in ant genera.”
Michael Hunkapiller, Ph.D., Chairman and CEO of PacBio added:
“Novogene has very quickly become the largest user of our Sequel
platform, and is now operating the largest SMRT Sequencing service
center in the world. We are delighted that they have successfully
ramped up their utilization of the systems so quickly, and that
high demand for SMRT Sequencing services in China has led them to
already increase their capacity.”
About Pacific Biosciences
Pacific Biosciences of California, Inc. (NASDAQ:PACB)
offers sequencing systems to help scientists resolve genetically
complex problems. Based on its novel Single Molecule, Real-Time
(SMRT®) technology, Pacific Biosciences’ products enable: de novo
genome assembly to finish genomes in order to more fully identify,
annotate and decipher genomic structures; full-length transcript
analysis to improve annotations in reference genomes, characterize
alternatively spliced isoforms in important gene families, and find
novel genes; targeted sequencing to more comprehensively
characterize genetic variations; and real-time kinetic information
for epigenome characterization. Pacific Biosciences’ technology
provides high accuracy, ultra-long reads, uniform coverage, and the
ability to simultaneously detect epigenetic changes. PacBio®
sequencing systems, including consumables and software, provide a
simple, fast, end-to-end workflow for SMRT Sequencing. More
information is available at www.pacb.com.
About Novogene Corporation Novogene is a
leading provider of genomic services and solutions with cutting
edge NGS and bioinformatics expertise and one of the largest
sequencing capacities in the world. Novogene utilizes scientific
excellence, a commitment to customer service and unsurpassed data
quality to help our clients realize their research goals in the
rapidly evolving world of genomics. With 1,800 employees, multiple
locations around the world, 49 NGS related patents, and over 250
publications in top tier journal such as Nature and Science, the
company has rapidly become a world-leader in NGS services. For more
information, visit https://en.novogene.com/.
Forward-Looking StatementsAll statements in
this press release that are not historical are forward-looking
statements, including, among other things, statements relating to
product orders, future uses, quality or performance of, or benefits
of using, products or technologies, the expected benefits of the
company’s agreement with Novogene, the suitability of the company’s
products for particular markets or applications and other future
events. You should not place undue reliance on forward-looking
statements because they involve known and unknown risks,
uncertainties, changes in circumstances and other factors that are,
in some cases, beyond Pacific Biosciences’ control and could cause
actual results to differ materially from the information expressed
or implied by forward-looking statements made in this press
release. Factors that could materially affect actual results can be
found in Pacific Biosciences’ most recent filings with
the Securities and Exchange Commission, including Pacific
Biosciences’ most recent reports on Forms 8-K, 10-K and 10-Q, and
include those listed under the caption “Risk Factors.” Pacific
Biosciences undertakes no obligation to revise or update
information in this press release to reflect events or
circumstances in the future, even if new information becomes
available.
Contacts for PacBio:
Media:
Nicole Litchfield
415.793.6468
nicole@bioscribe.com
Investors:
Trevin Rard
650.521.8450
ir@pacificbiosciences.com
For Novogene:
Joyce Peng, Ph.D.
Global Marketing Director and General Manager
San Diego, California
+1-626-222-5584
joyce.peng@novogene.com
Pacific Biosciences of C... (NASDAQ:PACB)
Historical Stock Chart
From Mar 2024 to Apr 2024
Pacific Biosciences of C... (NASDAQ:PACB)
Historical Stock Chart
From Apr 2023 to Apr 2024